AU2003280471B2 - Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers - Google Patents

Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Download PDF

Info

Publication number
AU2003280471B2
AU2003280471B2 AU2003280471A AU2003280471A AU2003280471B2 AU 2003280471 B2 AU2003280471 B2 AU 2003280471B2 AU 2003280471 A AU2003280471 A AU 2003280471A AU 2003280471 A AU2003280471 A AU 2003280471A AU 2003280471 B2 AU2003280471 B2 AU 2003280471B2
Authority
AU
Australia
Prior art keywords
cancer
hyaluronan
cell
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003280471A
Other languages
English (en)
Other versions
AU2003280471A1 (en
Inventor
Shibnath Ghatak
Suniti Misra
Bryan P. Toole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of AU2003280471A1 publication Critical patent/AU2003280471A1/en
Application granted granted Critical
Publication of AU2003280471B2 publication Critical patent/AU2003280471B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003280471A 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Ceased AU2003280471B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39290502P 2002-07-01 2002-07-01
US60/392,905 2002-07-01
US45376103P 2003-03-11 2003-03-11
US60/453,761 2003-03-11
PCT/US2003/020918 WO2004003545A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Publications (2)

Publication Number Publication Date
AU2003280471A1 AU2003280471A1 (en) 2004-01-19
AU2003280471B2 true AU2003280471B2 (en) 2009-04-23

Family

ID=30003285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003280471A Ceased AU2003280471B2 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Country Status (6)

Country Link
US (2) US8093217B2 (enExample)
EP (2) EP1532434A4 (enExample)
JP (2) JP5027387B2 (enExample)
AU (1) AU2003280471B2 (enExample)
CA (1) CA2513143A1 (enExample)
WO (1) WO2004003545A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
AU2005287397A1 (en) * 2004-06-30 2006-03-30 Paul L. Deangelis Methods of selectively treating diseases with specific glycosaminoglycan polymers
CA2609467A1 (en) * 2005-05-26 2006-11-30 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
EP2079846A4 (en) * 2006-10-03 2013-08-07 Univ Oklahoma TARGETED GLYCOSAMINOGLYCAN POLYMERS BY POLYMER GRAFTING AND MANUFACTURING AND USE METHOD THEREFOR
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
EP2097092A4 (en) * 2006-11-21 2010-04-07 MODULATION OF RHAMM (CD168) FOR THE SELECTIVE DEVELOPMENT OF ADIPOSIS TISSUE
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
EP2307571A4 (en) * 2008-06-26 2012-03-07 Univ South Florida PROOF AND SENSITIZATION PROCEDURE FOR THE PLATINUM RESISTANCE OF CANCER DISORDERS
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
RU2015123315A (ru) 2012-11-25 2017-01-10 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Пептиды, стимулирующие подкожный адипогенез
KR20160099081A (ko) * 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
EP3271383A4 (en) 2015-03-20 2019-06-12 London Health Sciences Centre Research Inc. GASED PEPTIDES AND USES THEREOF
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020131995A1 (en) * 1999-12-03 2002-09-19 Szoka Francis C. Targeted drug delivery with a cd44 receptor ligand
US20030026801A1 (en) * 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5976874A (en) * 1996-08-16 1999-11-02 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6420335B1 (en) * 1998-06-15 2002-07-16 Dana Farber Cancer Institute, Inc. Combination of radiotherapy and anti-angiogenic factors
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
JP2004505890A (ja) * 2000-04-04 2004-02-26 ノバルティス　アクチエンゲゼルシャフト 抗新生物剤に耐性の細胞を処置する方法
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020131995A1 (en) * 1999-12-03 2002-09-19 Szoka Francis C. Targeted drug delivery with a cd44 receptor ligand
US20030026801A1 (en) * 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yeo et al., American Journal of Pathology. 1996, Vol. 148, No. 6, pages 1733-40 (X) *

Also Published As

Publication number Publication date
EP2434282A2 (en) 2012-03-28
US20120095277A1 (en) 2012-04-19
US20040229843A1 (en) 2004-11-18
JP2005532373A (ja) 2005-10-27
AU2003280471A1 (en) 2004-01-19
WO2004003545A1 (en) 2004-01-08
US8093217B2 (en) 2012-01-10
WO2004003545A9 (en) 2004-04-15
EP2434282A3 (en) 2012-08-22
EP1532434A4 (en) 2009-05-27
EP1532434A1 (en) 2005-05-25
JP5027387B2 (ja) 2012-09-19
JP2010116410A (ja) 2010-05-27
CA2513143A1 (en) 2004-01-08
US8648047B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
US8648047B2 (en) Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
Munshi et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
KR100609646B1 (ko) Ｅｇｆ-ｒ 길항물질의 투여에 의한 기도 점액생산의 방지
Zhu et al. Inhibition of NADPH oxidase-ROS signal using hyaluronic acid nanoparticles for overcoming radioresistance in cancer therapy
Gong et al. Hyaluronic acid modified doxorubicin loaded Fe 3 O 4 nanoparticles effectively inhibit breast cancer metastasis
Wei et al. Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer
Teranishi et al. Phosphoinositide 3‐kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo
Zhang et al. CaCO3‐Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma
Bizzarro et al. Mesoglycan induces keratinocyte activation by triggering syndecan‐4 pathway and the formation of the annexin A1/S100A11 complex
EP2908858B1 (en) Compositions for use in inhibiting osteolysis
Deng et al. Inhibition of colorectal cancer aggressiveness by Oleanolic acid through Nur77 degradation
Kim et al. Hyaluronic acid fuels pancreatic cancer growth
Wang et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines
Kim et al. Suppression of tumor progression by thioredoxin-interacting protein-dependent adenosine 2B receptor degradation in a PLAG-treated Lewis lung carcinoma-1 model of non–small cell lung cancer
Davis et al. Novel suicide ligands of tubulin arrest cancer cells in S-phase
Walewska et al. PEG-liposomal doxorubicin as a potential agent for canine metastatic osteosarcoma–in vitro and ex ovo studies
Booth et al. GZ17-6.02 kills PDX isolates of uveal melanoma
WO2016100431A1 (en) Methods for treating inflammatory arthritis
Wei et al. Injectable thermosensitive hydrogel co-loading with ATRi and doxorubicin for the treatment of triple-negative breast cancer
US20240166702A1 (en) Compositions and methods for treating breast cancer
Rosen et al. Reduced CSF1R expression in myeloid cells has limited impact on chronic lymphocytic leukemia progression
Tsumura et al. Conditional deletion of CD98hc inhibits osteoclast development
Hampton et al. Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer
Szewczyk et al. Optimizing Jasplakinolide delivery in rhabdomyosarcoma cells using pulsed electric fields (PEFs) for enhanced therapeutic impact
Mısırlı et al. Effects of SPARC and Possible Receptors on Colon Cancer Cell Line

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTOR NAMES MISRA, SUNITI; GHATAK, SHIBNATH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired